TargED Biopharmaceuticals
Utrecht, NL · Founded 2018 · 40 employees on LinkedIn · 11 known investors
Find your way into TargED Biopharmaceuticals
976 people in our graph share verified history with the TargED Biopharmaceuticals team — schools, employers, funds. One of them is your warm intro.
René Kuijtenunlockedknows Steven de Maat · together at Utrecht University (overlapped)
×3knows the team · via GSK
knows the team · via Organon NV
knows the team · via Ablynx
knows the team · via University of Antwerp
×4knows the team · via Vlerick Business School
TargED is a biopharmaceutical company developing therapeutics for thrombotic disorders, spun out from University Medical Center Utrecht. The company focuses on bringing novel compounds from early-stage research to clinical development.
Founders & leadership
TargED Biopharmaceuticals was founded in 2018 by Coen Maas, Steven de Maat, Marc van Moorsel, and Kristof Vercruysse.
CM
Coen MaasinCo-founderCoen Maas is a researcher with extensive publications in his field, having authored or co-authored over 100 peer-reviewed articles and supervised multiple doctoral candidates. He is co-founder of TargED Biopharmaceuticals, a spinout from University Medical Center Utrecht developing therapeutics for thrombotic disorders.
SD
Steven de MaatinChief Scientific OfficerSteven de Maat holds a PhD and has conducted research on bradykinin production and microvascular thrombosis, leading to work on selective modification of SERPINs for therapeutic applications in bradykinin-mediated disease. He co-founded TargED Biopharmaceuticals (formerly SERPINx BV) and currently serves as Chief Scientific Officer.
MV
Marc van MoorselinDirector of OperationsDirector of Operations at TargED Biopharmaceuticals, a biopharmaceutical company developing therapeutics for thrombotic disorders that was spun out from University Medical Center Utrecht.
KV
Kristof VercruysseinChief Executive OfficerKristof Vercruysse is CEO of TargED Biopharmaceuticals, a biopharmaceutical company developing therapeutics for thrombotic disorders spun out from University Medical Center Utrecht. He has led the advancement of drug candidates from preclinical studies through human proof-of-concept trials and brings experience in pharmaceutical development strategy, project leadership, and orphan drug programs.
RD
Rob DekkerinVice President CMCRob Dekker brings nearly 30 years of experience in pharmaceutical manufacturing science, regulatory strategy, and quality management. At TargED Biopharmaceuticals, he leads chemistry, manufacturing, and controls efforts for the company's thrombotic disorder therapeutics.
FV
Filip Van den WyngaertinVice President Asset ManagementHe has held leadership roles in pharmaceutical and biotech development across multiple geographies and therapeutic stages, with experience in asset strategy and organizational scaling.
DS
Dr. Samuel WhiteChief Business Officer
JH
Josi HolzinChief Medical OfficerJosi Holz completed medical oncology training at the University of Marburg and brings over 30 years of pharmaceutical drug development experience across Europe and North America, including more than two decades in executive roles overseeing translational medicine, clinical development, and regulatory strategy across oncology, immunology, hematology, and other therapeutic areas.
Investors · 11
Andera PartnersParis
Curie CapitalAmsterdam
Fund+Leuven · $5.5M – $16.5M
Hadean VenturesOslo
RotripAmsterdam
BioGeneration Venturesreported · 3 sourcesNaarden
Inkefreported · 3 sourcesAmsterdam
Sunstone CapitalreportedFrederiksberg
Also in the syndicate · 3
FIRSTSunstone Life Science VenturesUtrecht Health Seed Fund
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AJul 2025Source ↗
- Undisclosed amountSeries AFeb 2022 · 2 sources
Andera Partners, BioGeneration Ventures, Curie Capital, FIRST, Fund+, Hadean Ventures, Inkef Capital, Sunstone Life Science Ventures, Utrecht Health Seed Fund
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does TargED Biopharmaceuticals do?
- TargED is a biopharmaceutical company developing therapeutics for thrombotic disorders, spun out from University Medical Center Utrecht. The company focuses on bringing novel compounds from early-stage research to clinical development.
- Who founded TargED Biopharmaceuticals?
- TargED Biopharmaceuticals was founded by Coen Maas, Steven de Maat, Marc van Moorsel, Kristof Vercruysse in 2018.
- Who are TargED Biopharmaceuticals's investors?
- TargED Biopharmaceuticals's investors include Andera Partners, Curie Capital, Fund+, Hadean Ventures, Rotrip, BioGeneration Ventures, Inkef, Sunstone Capital.
- Where is TargED Biopharmaceuticals headquartered?
- TargED Biopharmaceuticals is headquartered in Utrecht, NL.